Skip to Content


Active Substance: nelfinavir
Common Name: nelfinavir
ATC Code: J05AE04
Marketing Authorisation Holder: Roche Registration Ltd.
Active Substance: nelfinavir
Status: Withdrawn
Authorisation Date: 1998-01-22
Therapeutic Area: HIV Infections
Pharmacotherapeutic Group: Antivirals for systemic use

Therapeutic Indication

Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older.

In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.

The marketing authorisation for Viracept has not been renewed by the marketing-authorisation holder and is now withdrawn.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.